Cargando…
Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil(®)) to Tumour Cells Using a Novel TIMP3 Peptide
Doxorubicin is a cytotoxic anthracycline derivative that has been used as a chemotherapeutic in many different forms of human cancer with some success. However, doxorubicin treatment has several side-effects, the most serious of which is cardiomyopathy, that can be fatal. Doxorubicin encapsulation i...
Autores principales: | Aldughaim, Mohammed S., Muthana, Munitta, Alsaffar, Fatimah, Barker, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795762/ https://www.ncbi.nlm.nih.gov/pubmed/33379361 http://dx.doi.org/10.3390/molecules26010100 |
Ejemplares similares
-
Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site
por: Aldughaim, Mohammed S., et al.
Publicado: (2021) -
Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
por: Nordström, Rickard, et al.
Publicado: (2021) -
Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002) -
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002) -
Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil(®)) in C26 Tumor-Bearing Immunocompetent Mice
por: Takayama, Takuma, et al.
Publicado: (2020)